Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veverka

Showing results (11-20 of 420) with videos related to

Pageof 42
Sort By:
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|June 6, 2023
Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local RecurrenceKevin K Veverka, Erik J Stratman
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 15, 2024
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic DermatitisFerda Cevikbas, Alison Ward, Karen A Veverka
Biochemical Society Transactions|January 18, 2023
The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and disorderKaterina Cermakova, Vaclav Veverka, H Courtney Hodges
Dermatitis : Contact, Atopic, Occupational, Drug|January 7, 2020
Dubiously Doubtful: An Exploration of the Literature Concerning Doubtful, Macular Erythema, "?+," and "+/-" Patch Test ReactionsKevin K Veverka, Mark D P Davis
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 17, 2014
Improving pharmacist documentation of clinical interventions through focused educationKatherine B Rector, Angie Veverka, Stacie Krick Evans
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 8, 2011
Risk of cancer associated with the use of angiotensin II-receptor blockersJacqueline L Olin, Angie Veverka, Donald S Nuzum
Vascular Health and Risk Management|April 2, 2009
Long-acting nifedipine in the management of the hypertensive patientMorgan E Snider, Donald S Nuzum, Angie Veverka
Critical Reviews in Food Science and Nutrition|June 29, 2022
Understanding the health benefits and technological properties of β-glucan for the development of easy-to-swallow gels to guarantee food security among seniorsMelina Korčok, Jehannara Calle, Miroslav Veverka, et al.
Clinical Immunology (Orlando, Fla.)|June 14, 2023
Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteersFerda Cevikbas, Alison Ward, Carl Firth, et al.
The Annals of Pharmacotherapy|July 11, 2006
Nebivolol: a third-generation beta-adrenergic blockerAngie Veverka, Donald S Nuzum, Jamie L Jolly
Pageof 42

Showing results (11-20 of 420) with videos related to

Sort By:
Pageof 42
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|June 6, 2023
Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local RecurrenceKevin K Veverka, Erik J Stratman
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 15, 2024
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic DermatitisFerda Cevikbas, Alison Ward, Karen A Veverka
Biochemical Society Transactions|January 18, 2023
The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and disorderKaterina Cermakova, Vaclav Veverka, H Courtney Hodges
Dermatitis : Contact, Atopic, Occupational, Drug|January 7, 2020
Dubiously Doubtful: An Exploration of the Literature Concerning Doubtful, Macular Erythema, "?+," and "+/-" Patch Test ReactionsKevin K Veverka, Mark D P Davis
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 17, 2014
Improving pharmacist documentation of clinical interventions through focused educationKatherine B Rector, Angie Veverka, Stacie Krick Evans
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 8, 2011
Risk of cancer associated with the use of angiotensin II-receptor blockersJacqueline L Olin, Angie Veverka, Donald S Nuzum
Vascular Health and Risk Management|April 2, 2009
Long-acting nifedipine in the management of the hypertensive patientMorgan E Snider, Donald S Nuzum, Angie Veverka
Critical Reviews in Food Science and Nutrition|June 29, 2022
Understanding the health benefits and technological properties of β-glucan for the development of easy-to-swallow gels to guarantee food security among seniorsMelina Korčok, Jehannara Calle, Miroslav Veverka, et al.
Clinical Immunology (Orlando, Fla.)|June 14, 2023
Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteersFerda Cevikbas, Alison Ward, Carl Firth, et al.
The Annals of Pharmacotherapy|July 11, 2006
Nebivolol: a third-generation beta-adrenergic blockerAngie Veverka, Donald S Nuzum, Jamie L Jolly
Pageof 42